基本信息
views: 64
Career Trajectory
Bio
Nicanor III Obaldia Rodriguez is a veterinarian who graduated from the National University of Colombia-Bogota with a Master of Science from the University of Wisconsin-Madison and a Doctor of Science in Immunology and Infectious Diseases / Public Health from Harvard University - School of Public Health. In collaboration with Harvard, the University of Glasgow, Scotland, UK, and the University of Zurich, Switzerland he is investigating the immunology and efficacy of Plasmodium vivax blood stages whole organisms vaccines. As a senior scientist, he is also interested in helping to translate scientific findings to improve antimalarial drug policy for transmissible areas of Panama and Meso-America. He is also involved in effectively addressing pressing health problems in Panama (where malaria and dengue are endemic) and become a leader in the field in Panama and the region.
In 2015, Dr. Obaldia was elevated to the category of Fellow of the American Society of Tropical Medicine and Hygiene (FASTMH) and in 2010 was awarded the General William C. Gorgas Gold Medal of Scientific Merit by the Gorgas Memorial Institute of Health Studies in Panama, in recognition of his scientific contributions to the field of malaria drug and vaccine development. Since 2021 Dr. Obaldia is a Fellow member of the Royal Society of Medicine (FRSM), London, UK.
Malaria remains a major cause of morbidity and mortality around the world, nevertheless, little is known about antimalarial drugs modes of action and the resistance patterns of the parasite. The objective of Dr. Obaldia's work is to test the pharmacokinetics and efficacy of new antimalarial compounds, the molecular mechanisms of drug resistance and pathogenesis of the parasite, as well as, to test the immunogenicity and efficacy of antimalarial vaccines.
The approach Dr. Obaldia's laboratory has taken is to test new antimalarial compounds against multiple-drug resistant Plasmodium falciparum and P. vivax laboratory adapted strains in vitro and in vivo in animal models of disease. Using the Aotus / P. falciparum animal model, his group has been able to test the pharmacokinetics and efficacy of several classes of compounds alone or in combination, including but not limited to: 4 and 8-aminoquinolines, artemisinin derivatives (artesunate, artheeter, arthemeter), quinoline- methanol derivatives, antifolates, and antimicrobials. He has also been able to study the pathogenesis and drug resistance profiles of multiple-drug resistant Thai and New-Guinea parasites such as the P.falciparum C2A and P. vivax AMRU-1 strains respectively.
In another aspect of his research, Dr. Obaldia has tested the efficacy and immunogenicity of antimalarial vaccines in the erythrocytic challenge Aotus model, through the use of repeated challenge, plasmid DNA vaccines, temperature-sensitive mutants, synthetic peptides, recombinant proteins, and to test the immunogenicity of toxoplasma temperature-sensitive mutants and hepatitis B plasmid DNA vaccines. Evidence from his laboratory has suggested that the mechanism of malaria parasite transmission through gametocytogenesis is shut down in some strains, after serial passage in non-human primate through a suspected epigenetic mechanism. Recently, he has been studying this mechanism in the multiple resistant non-human primate serially adapted C2A strain of P. falciparum using new molecular tools such as the P. falciparum barcode.
Research Interests
Papers共 63 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
ANTIMICROBIAL AGENTS AND CHEMOTHERAPYno. 7 (2024)
LIFE SCIENCE ALLIANCEno. 3 (2024)
bioRxiv (Cold Spring Harbor Laboratory) (2023)
crossref(2023)
biorxiv(2023)
Research Square (Research Square) (2021)
Cited0Views0Bibtex
0
0
Load More
Author Statistics
#Papers: 62
#Citation: 1317
H-Index: 21
G-Index: 36
Sociability: 6
Diversity: 2
Activity: 5
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn